PXMD
PAXMEDICA INC
Latest price
As of — · Market data by Massive
Market cap
—
Volume
0
Previous close
$0.0007
Day range
$0.0000 – $0.0000
Listed
—
Coverage
10 articles
Price performance
Recent trading
Newsroom
Latest PXMD coverage
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
[ad_1] · Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years · VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as well as additional offerings for People diagnosed with Autism and their Families TARRYTOWN, NY and HUDSON, OH – (NewMediaWire) – July 06, 2023
PaxMedica Comments on Common Stock Volatility
[ad_1] Engages ShareIntel to Track Market Activity TARRYTOWN, NY – (NewMediaWire) – June 22, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intra
PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder
[ad_1] Collaboration Will Investigate a Next Generation Orally Delivered Anti-Purinergic Compound Proof-of-Concept Study Based on one of PaxMedica’s Proprietary Pipeline Candidates TARRYTOWN, NY – (NewMediaWire) – June 08, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of nove
PaxMedica Completes HAT-301 Registrational Trial for PAX-101
[ad_1] HAT-301 is the Pivotal Efficacy Study to Support Upcoming NDA Filing Top Line Results Planned for Release in July 2023 TARRYTOWN, NY – (NewMediaWire) – June 01, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatm
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
[ad_1] TARRYTOWN, NY – (NewMediaWire) – May 15, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for
PaxMedica Releases 2022 Shareholder Letter
[ad_1] Company Anticipates Multiple Milestones in Next 12-24 Months TARRYTOWN, NY – (NewMediaWire) – February 15, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms,
PaxMedica, Inc. Secures $3.2 Million Growth Capital from Lind Partners
[ad_1] Additional Capital Will Help Fund Development of PAX-101 TARRYTOWN, NY – (NewMediaWire) – February 03, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, tod
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event
[ad_1] Presentation on Thursday, January 26th, 2023 at 1:30 PM EST TARRYTOWN, NY – (NewMediaWire) – January 20, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, tod
PaxMedica to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference
[ad_1] TARRYTOWN, NY – (NewMediaWire) – November 22, 2022 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced it will be presenting at the Benchmark Company
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
[ad_1] -Agreement Provides Flexible Funding on Path to NDA Submission for PAX-101- TARRYTOWN, NY – (NewMediaWire) – November 17, 2022 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neuro